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Employing antibodies against the cytoplasmic tail of the HIV-1 glycoprotein (Env-CT), in addition to
gp160/gp41, we have identiﬁed several novel small Env proteins (o25 kD) in HIV-1 transfected and
infected cells. Mass spectrometric and mutational analyses show that two mechanisms contribute to
their generation. Thus the protein, designated Tr-Env-CT (for truncated Env-CT), consists of the C-
terminal 139 amino acids (aa) of Env (aa 718–856) with the N-terminal Q718 modiﬁed to pyroglutamic
acid. It is likely derived from full-length Env protein by proteolytic processing. A further heterogeneous
set of slightly larger proteins, termed Env-CT* species, are rather derived from spliced mRNAs containing
only those Env C-terminal residues (aa 719–856) which overlap with the second tat and rev coding exons.
They are N-terminally extended in the same reading frame. It is conceivable that essential Env-CT
functions may be fulﬁlled by these novel species rather than by the full-length glycoprotein itself.
& 2013 Elsevier Inc. All rights reserved.Introduction
A conserved feature of most lentiviral glycoproteins, including
the Env glycoprotein of human immunodeﬁciency virus type 1
(HIV-1), is the presence of a very long cytoplasmic tail region (Env-
CT) which, in the case of HIV, is 151 amino acids (aa) long). The
existence of an HIV Env-CT region is extremely highly conserved
in vivo and, in the simian immunodeﬁciency virus/monkey model,
truncation of the Env-CT leads to suppression of viral replication
in vivo (Shacklett et al., 2000). The currently known structural and
functional properties of the HIV Env-CT are summarized in two
recent reviews (Checkley et al., 2011; Postler and Desrosiers, 2012)
and will only be described here brieﬂy. In its central and
C-terminal region, the Env-CT contains three regions, termed
lentiviral lytic peptides (LLP1-3) regions which exhibit α-helical
potential and have been shown to interact with cellular mem-
branes (Chernomordik et al., 1994; Haffar et al., 1991). Presumably
mediated by its interaction with the viral matrix protein (MA), the
Env-CT has been proposed to play roles in Env incorporation into
virions (Freed and Martin, 1996) and in the regulation
of fusion between released virions and the membrane of target
cells (Murakami et al., 2004; Wyma et al., 2004). Two functionalll rights reserved.
e (V. Bosch).endocytosis motifs are also located in the Env-CT, namely a
membrane-proximal tyrosine-based signal (YxxL) and a C-terminal
dileucine motif (Env-LL855, 856), both of which operate indepen-
dently through interaction with clathrin adaptor protein com-
plexes (Berlioz-Torrent et al., 1999; Byland et al., 2007; Wyss
et al., 2001). The membrane-proximal YxxL motif has also been
shown to play a role in the basolateral targeting of Env (and Gag)
in polarised cells (Lodge et al., 1994, 1997). The Env-CT region has
also been shown to interact with a number of cellular proteins.
Thus, in addition to components of the endocytosis machinery, it
has been demonstrated that the Env-CT interacts with calmodulin
(Miller et al., 1993), TIP47 (Blot et al., 2003), the guanine nucleo-
tide exchange factor p115-RhoGEF (Zhang et al., 1999), prenylated
Rab receptor (Rab1) (Evans et al., 2002), catenin (Kim et al., 1999),
luman (Blot et al., 2006) and the dimer of cellular prohibitin 1
and prohibitin 2 (Phb1/Phb2) (Emerson et al., 2010b). In general,
the functional importance of these interactions have not been
elucidated.
It is important to note that most of the roles presently
attributed to the HIV-Env-CT region can be fulﬁlled by the
glycoproteins of other retroviruses, as well by the glycoproteins
of enveloped viruses in general, all of which carry much shorter CT
regions. This suggests that additional lentiviral Env-CT functions,
essential for viral replication and pathogenesis in vivo, still remain
to be elucidated.
In this study, we describe several novel Env proteins detected
in provirally transfected and infected cells which consist of amino
T. Pfeiffer et al. / Virology 441 (2013) 85–9486acid sequences derived from the Env-CT region but lacking the Env
membrane-spanning and ectodomains. The existence of these
species opens the possibility that essential lentiviral Env-CT
speciﬁc functions may, in fact, be implemented by these protein
moieties rather than by the Env-CT as part of the full-length
glycoprotein.Results
Novel protein moieties containing HIV Env-CT sequences
The HIV Env glycoprotein gp160 is cleaved by the cellular
protease furin into the surface gp120 (SU) and the transmembrane
gp41 (TM) proteins. The topology of the TM protein predicts that
its C-terminal cytoplasmic tail (Env-CT) consists of aa 706–856. A
schematic representation of HIV Env illustrating the positions of
features of relevance for this study is shown in Fig. 1A. Fig. 1B, lane 1,
shows Western blot analysis, employing Chessie 8 mAb (epitope
aa 727–732) of a lysate of 293 T cells transfected with wild type
proviral plasmid, pNL-Wt. In addition to the expected bands of
gp160 and gp41, a number of bands with molecular weights in
the range of approximately 13–20 kD were detected. The use of
the employed gradient gel system was important for the
proper separation of these different Env species. These novel
bands were absent employing unrelated mouse monoclonal anti-
bodies, e.g. SIM2 antibodies (against CD4), and were not detected
in lysates of untransfected cells. They were also not an artefact of
the use of the Chessie 8 mAb but were also detected employing
rabbit polyclonal antiserum against gp160 protein, which also
contains antibodies against the CT region (data not shown).
Further, the same Chessie 8 reactive species could be detected
on expression of a different HIV Env protein, namely THRO4156.18
Env (accession number AY835448, (Li et al., 2005)) which exhibits
20% amino acid sequence diversity in comparison to the Env
protein employed here (Fig. S1). The construct prec. Env-CT
expresses a recombinant protein consisting of the Env-CT region
(plus an N-terminal methionine) alone (see Fig. 1A). As can be seenFig. 1. (A) Schematic representation of the HIV glycoprotein. The region in the Env-CT be
732 is hatched, the splice acceptor site 7 (SA7) between aa 718 and 719 is marked and th
of the Env proteins expressed from prec.Env-CT and pNL-ΔEnv are given below. (B) Wes
with VSV-G pseudotyped virions. The plasmids employed in the individual lanes are ind
the positions of molecular weight markers are given and in both (B) and (C) the positions
the same gel as lanes 1–8 but shows a different (shorter) exposure.in Fig. 1B, lane 9, in line with its calculated size of 17.76 kD, this
protein migrated somewhat slower than the 15 kD marker band.
Thus the protein in the fastest migrating band in Fig. 1B, lane 1
(running faster than the 15 kD marker) is clearly smaller than the
entire Env-CT. It is designated Tr-Env-CT (for truncated Env-CT).
The generation of Tr-Env-CT was dependent on expression of full-
length Env protein and was not detectable on expression of pNL-
ΔEnv with a frame-shift at the beginning of the env gene, (Fig. 1B,
lane 6), or when Env proteins truncated within the CT region (from
proviral pNL-Env-Tr712 (Fig. 1B, lane 3) and pNL-Env-Tr-813
(Fig. 1B, lane 4) or from the subgenomic Env expression plasmid
pßAc-Env-Tr752 (Fig. 1B, lane 8)) were expressed. However, the
additional larger protein bands, seen on expression of pNL-Wt
(lane 1) and migrating slower than the 15 kD marker band, were
also detected on expression of pNL-ΔEnv as well as in some of the
other lanes in somewhat varying amounts. Since pNL-ΔEnv does
not express Env protein at all, these heterogeneous bands (referred
to here as Env-CT* bands) were initially regarded as representing
some sort of background artefact. However, as will be discussed
later, this is not the case but rather the Env-CT* bands turned out
to be speciﬁc spliced Env-CT isoforms with N-termini which are
not derived from Env protein. In Fig. 1C, Western blot analysis of
lysates of C8166 T-cells expressing pNL-Wt and pNL-Env-Tr712
after infection with pseudotyped virions is shown. The same Env-
CT-related protein species as seen in the transfected 293 T cells
were seen, albeit in lower amounts.Generation of Tr-Env-CT
Our initial focus was on the elucidation of the identity and
mode of generation of the Tr-Env-CT protein. Tr-Env-CT was
still generated in cells transfected with pNL-Wt incubated in the
presence of HIV protease inhibitor, Saquinivir, as well as from the
subviral Env expression vector pßAc-Env (Fig. 1B, lanes 2 and 7).
The effectiveness of the Saquinivir treatment was conﬁrmed by
analysis of HIV Gag protein expression which showed that
only precursor Pr55gag and no p24 was present (Fig. S2).tween Env aa 706 and 732 is expanded. The Chessie 8 epitope between aa 727 and
e C-termini of the employed Env truncations are shown by stars (*). The dimensions
tern blot analysis of lysates of transfected 293 T cells and of C. C8166 cells infected
icated on the right. In all cases, Env-CT antibodies (Chessie 8) were employed. In B.
of detected HIV-Env proteins are indicated on the left. Note that in (B) lane 9 is from
Fig. 2. Western blot analysis of lysates of 293 T cells transfected with pCMV-Env
(Wt) and pCMV-Env-C-Flag and probed with Env-CT (Chessie 8) antibodies (left) or
anti-Flag antibodies (right). The positions of molecular weight markers are shown
in the middle and of detected HIV-Env proteins on the left.
Table 1
Peptides detected in puriﬁed gp41 and Tr-Env-CT proteins.
Peptide Env aa Detection Ratio Tr-Env-CT/gp41
QLLSGIVQQQNNLLR 543–557 Gp41/Tr-Env-CT 0.06
AIEAQQHLLQLTVWGIK* 558–574 Gp41 –
YLKDQQLLGIWGCSGK 586–601 Gp41 –
NEQELLELDK 656–665 Gp41 –
QGYSPLSFQTHLPIPR 710–725 Gp41 –
GPDRPEGIEEEGGER 726–740 Gp41/Tr-Env-CT 1.4
LVNGSLALIWDDLR* 748–761 Gp41/Tr-Env-CT 1.1
SLCLFSYHR 762–770 Gp41/Tr-Env-CT 1.7
LRDLLLIVTR* 771–780 Gp41/Tr-Env-CT 1.5
DLLLIVTR 773–780 Gp41/Tr-Env-CT 1.3
RGWEALK 788–795 Tr-Env-CT –
NSAVSLLNATAIAVAEGTDR* 809–828 Gp41/Tr-Env-CT 0.6
VIEVVQGAYR 829–838 Gp41/Tr-Env-CT 0.8
The detected peptides (sequenced by MS/MS), their positions within the Env
protein sequence and whether detected in puriﬁed gp41, Tr-Env-CT or both is given.
Peptide intensities were calculated by the label free quantitation tool of the
MaxQuant Software. In the right column the ratios of the intensities of the
individual peptides from gp41 in comparison to the intensities of the same peptides
from Tr-Env-CT are given. Peptides marked with an asterisk were detected in
different charge states and the average Tr-Env-CT/gp41 ratio taken.
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enzyme nor does its generation require HIV sequences outside of
pNL4-3 nucleotides 5785–8887. The generation of Tr-Env-CT also
does not depend on the sequence of the Env membrane spanning
domain (TMD, Env aa 684–705) since it was still produced from
pNL-Env-TMD-CD22 in which the HIV-Env-TMD has been replaced
with that of the type 1 glycoprotein CD22 (Fig. 1B, lane 5). In order
to analyse if Tr-Env-CT contains the Env C-terminus, expression
from pCMV-Env-Flag, carrying tandem Flag sequences within 23
additional amino acids at the Env C-terminus, was examined
employing Flag antibodies. Flagged gp160 and gp41 (this migrat-
ing somewhat slower than unﬂagged gp41), as well as a band
migrating slower than the 15 kD marker, were observed (Fig. 2,
right panel). Since this band also additionally reacted with Chessie 8
(Fig. 2, left panel), it represents a ﬂagged version of Tr-Env-CT
showing that Tr-Env-CT carries the Env C-terminus.
Determination of the Tr-Env-CT N-terminus
As demonstrated until now, Tr-Env-CT carries both the Env C-
terminus as well as the Chessie 8 epitope which is located only 21
aa C-terminal from the Env TMD (see Fig. 1A). Since Tr-Env-CT is
smaller than the Env-CT itself (as expressed from prec.Env-CT), its
N-terminus is deduced to lie within the Env aa sequence between
the TMD and the Chessie 8 epitope (i.e. within aa 706–727). To
conﬁrm the identity of Tr-Env-CT and to determine its N-terminus,
we used mass spectrometry to analyse the tryptic peptides
generated after in-gel digest of puriﬁed Tr-Env-CT and gp41
protein bands. To prepare these, Chessie 8 reactive bands were
immunoprecipitated from lysates of 2 large (18 cm diameter)
dishes of 293 T cells transfected with pßAc-Env-Wt. Initial analysis
of small aliquots (2–3% of total) of the precipitated proteins
conﬁrmed speciﬁc immunoprecipitation with an efﬁciency of
approximately 10–20% of the total (data not shown). The remain-
ing 97–98% of the immunoprecipitate was then applied to a single
slot of a gel which was subsequently stained with Coomassie blue.
There were no visible bands of gp41 or Tr-Env-CT but, with the
orientation provided by the applied marker proteins, gel slices at
the respective positions were excised. The tryptic peptides identi-
ﬁed in gp41 and Tr-Env-CT, respectively are given in Table 1 and
for Tr-Env-CT are shown schematically in Fig. 3B. As to be
expected, in the case of the gp41, the peptides were located
throughout the protein while most of the identiﬁed tryptic
peptides in the Tr-Env-CT band were within the Env-CT region.An exception was a single peptide from the gp41 ectodomain
which was presumably a contaminant from a breakdown product
of gp41 or gp160 present in the same gel slot. The ratio of the
individual peptide intensities derived from the gp41 and Tr-Env-
CT proteins (Table 1) supports this conclusion. The value for the
contaminating gp41 ectodomain peptide was much lower (0.06)
than the values for all of the other shared peptides (0.6–1.7). These
latter values further indicate that, at any rate in this transfected
293 T cell lysate, the molar amount of Tr-Env-CT was in the same
range as that of gp41.
The most N-terminal tryptic peptide identiﬁed in Tr-Env-CT
was located at aa 726–740 (see Table 1 and Fig. 3B) whereas in the
case of gp41 further N-terminal peptides including that at position
710–725 (QGYSPLSFQTHLPIPR) could be identiﬁed (Table 1). We
therefore subsequently concentrated on the identiﬁcation of a
Tr-Env-CT peptide starting with a non-tryptic N-terminus and
containing aa sequences N-terminal to Env aa 726. Using the error
tolerant search option of the Mascot software, which tolerates a
single unknown modiﬁcation within a peptide, the peptide
QTHLPIPR could be identiﬁed with high Mascot score. This
identiﬁcation indicated that the N-terminus of Tr-Env-CT is located
at Env residue Q718. This means that Tr-Env-CT is 139 aa long (see
Fig. 3B) and is thus 13 aa (12 aa plus initiation methionine) shorter
than the Env-CT protein expressed from prec.Env-CT. This is
consistant with its gel mobility. The peptide mass of the QTHLPIPR
peptide and the series of y-fragments (the peptide fragments
generated during sequencing) of this peptide (shown in Fig. 3A)
indicated, however, that the N-terminal glutamine residue had
been modiﬁed to pyroglutamic acid (pGlu). This modiﬁcation is
catalysed by cellular glutaminyl cyclase (QC), of which two
different isoenzymes exist. In the cells of relevance here (trans-
fected 293 T kidney cells and infected T-lymphocytes) the Golgi-
localised isoQC enzyme is likely to be responsible. In general,
modiﬁcation of N-terminal glutamine to pGlu has been described
to increase protein (or peptide) stability and biological activity.
A likely hypothesis to account for the generation of Tr-Env-CT is
that it is derived from full-length Env protein by proteolytic
processing. Fig. 3C illustrates the aa sequence in the vicinity of
the N-terminal pGlu of Tr-Env-CT. The percentage conservation of
each residue (as evaluated using the Quickalign tool with refer-
ence to the 2011 web alignment provided by the HIV Database, Los
Alamos, New Mexico, USA (http://www.hiv.lanl.gov/) is shown and
illustrates that a long stretch of highly conserved aa is located
Fig. 3. (A) MSMS spectrum of 718-pGluTHLPIPR-725. A doubly protonated peptide with m/z¼472.77 was selected for fragmentation. The sequence …HLPIPR is clearly
detected by the y-fragments 1 to 6. The difference between the peptide mass and the mass of the y6 fragment can only be explained by an N-terminal glutamine residue that
had been modiﬁed to pyroglutamic acid (pGlu) given that the second amino acid threonine is correct. (B) Derived amino acid sequence of Tr-Env-CT (Env aa 718-856). The
grey blocks indicate regions covered by identiﬁed tryptic peptides and the hatched grey box the N-terminal peptide with modiﬁed glutamine 718 (pyr-Q). The amino acids in
the Chessie 8 epitope are indicated. (C) Amino acid sequence and percentage conservation of the Env aa in the vicinity of Env Q718 as determined using the Quickalign tool
with reference to the 2011 web alignment provided by the HIV Database, Los Alamos, New Mexico, USA (http://www.hiv.lanl.gov/). The border of the Env membrane anchor
(TMD) and the cytoplasmic domain (CT) as well as the junction of splice acceptor (SA7) are shown. The position of the N-terminus of the Tr-Env-CT protein is indicated.
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known processing proteases (searched using the tool http://web.
expasy.org/peptide_cutter) could not be identiﬁed within this
region and mutation of individual aa did not prevent generation
of Tr-Env-CT (not shown). Nevertheless, since numerous cellular
proteases lack consensus cleavage motifs but rather recognise
structural motifs, we still favour proteolytic processing as the
most likely mechanism for the generation of Tr-Env-CT. Future
studies may throw more light on these issues.
Env-CT* amounts increased in the absence of rev.
As documented in Fig. 1B, the slightly larger set of heterologous
species, designated Env-CT*, was also generated from pNL-ΔEnv
which, as a result of a frame-shift mutation at the beginning of the
env gene, fails to express Env proteins (and also does not express
Tr-Env-CT). It was thus conceivable that the Env-CT* species were
expressed from spliced mRNAs. In order to investigate this,
expression from pNL-(rev-), encoding a defective truncated Revprotein (Rev-Tr62) was analysed. In the absence of functional Rev,
only spliced HIV mRNAs are efﬁciently transported to the cyto-
plasm and translated (Dayton et al., 1988; Malim et al., 1988).
Importantly, in pNL-(rev-), the env gene is intact and, in principle,
encodes only minimally altered Env protein. As expected, pNL-
(rev-) expresses neither Gag nor gp160 and gp41 proteins (Fig. 4A).
However, Env-CT* species were strongly increased pointing to
their production being by a mechanism independent of Env
expression, most probably by expression from fully spliced Rev-
independent mRNA.
Expression of Env-CT* species from prespliced (SD4–SD7) vector
The Env aa sequence 719–856, containing the Chessie 8 epitope,
is located downstream of splice acceptor 7 (see Fig. 1A), and is
present on nearly all HIV mRNA species whether full-length,
partially or fully spliced. In the majority of fully spliced mRNAs
(encoding Tat and Rev), splice donor 4 (SD4) has been joined to
splice acceptor 7 (SA7). pLTRctat/crev, schematically depicted in
SD1 SD4
SA2
SA7
gag
pol
env
Fig. 4. (A) Western blot analysis of lysates of 293 T cells transfected with pNL-Wt and the rev-defective derivative pNL-(rev-). The antibodies employed are indicated below
the respective images. (B) Schematic depiction of the construct pLTR-ctat/crev. The entire HIV genome is given with the positions of relevant splice donor (SD) and splice
acceptor (SA) sites indicated. The HIV sequences remaining in pLTR-ctat/crev are shown in brackets below. (C) Western blot analysis with Chessie 8 antibodies of 293 T cells
transfected with pNL-Wt, pLTR-ctat/crev and the derivative pLTR-ctat/crev-(rev-) (left blot) and with pLTR-ctat/crev and the ﬂagged derivative pLTR-ctat/crev-Flag (right
blot). The positions of the upper (u) and lower (l) regions of the Env-CT* species which have been separately analysed by mass spectrometry are indicated.
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splicing event. In this construct, splice donor 1 (SD1) has been
recombinantly joined to splice acceptor 2 (SA2) and SD4 to SA7
(Schaal et al., 1993). The construct encodes Vif and Vpr and, as a
result of recombinant splicing between SD4 and SA7, expresses the
spliced gene products Tat and Rev. The derivative pLTRctat/crev-
(rev-) encodes defective truncated Rev protein (Rev-Tr62). Wes-
tern blot analysis of lysates of cells transfected with these
constructs employing Chessie 8 antibodies is shown Fig. 4C, left
panel. A similar set of Env-CT* species as seen in a lysate of cells
transfected with pNL-(rev-) (plus an additional slightly larger band
present in variable amounts) were detected and again the expres-
sion of these protein entities was independent of Rev expression
(Fig. 4C, left panel). In order to study if these protein entities
contained the Env C-terminus, lysates of cells transfected with
pLTRctat/crev-Flag carrying 23 additional C-terminal aa (with
tandem Flag epitopes) were examined. Expressed proteins reacted
with both Flag antibodies (not shown) and Chessie 8 antibodies
and migrated slightly slower than the unﬂagged versions (Fig. 4C,
right panel), which shows that they all contain the HIV-Env
C-terminus (Fig. 4C, right panel).
Narrowing down the identity of the Env-CT* species
The Env-CT* species contain the Env-C-terminus and the
Chessie 8 epitope and are larger (migrate more slowly in gel) than
Tr-Env-CT. This means that the Env-CT* species are expected tocontain additional N-terminal amino acids upstream of Env aa
719–856 which are encoded in pLTR-ctat/crev. Thus, in order to
gain further information as to their identities, mass spectrometric
analysis of puriﬁed Env-CT* species was performed. Immunopre-
cipitation from lysates of pLTRctat/crev transfected cells was
carried out as previously described for gp41 and Tr-Env-CT. Two
gel slices containing the upper (u) and lower (l) Env-CT* species
(as labelled in Fig. 4C) were excised, trypsin digestion performed
and the aa sequences of the identiﬁed peptides screened against
all the HIV open reading frames (ORF) present in pLTRctat/crev. In
Fig. 5A, a region of the ORF potentially encoding the Env-CT
sequences is shown. The region between a stop codon at position
þ45 (i.e. upstream from Env aa 719) and the Env stop codon is
depicted. Presumably due to limitations in amounts of protein,
only a few peptides could be identiﬁed and only in the upper Env-
CT* band. However, all of the identiﬁed peptides were in the
depicted ORF. Three of the peptides were entirely within the
Env-CT but in the case of the identiﬁed tryptic peptide ATHLPIPR,
the N-terminal alanine residue, is upstream (þ1 position) of
the Env-CT sequence (and is preceded by a K residue).
The fragment spectrum of this peptide is shown in Fig. 5B. This
shows that amino acids in the same ORF but upstream of Env aa
739 are contributing to the larger size of the Env-CT* species. In
order to conﬁrm this involvement of upstream in-frame aa, we
introduced a stop codon in the upstream region, namely at Kþ2.
Fig. 5C shows a Western blot of lysates of cells transfected with
pLTR-ctat/crev and this derivative. The introduced stop codon
Stop-KVLLSLPSLFHDKSLRHLLWQEEAETATKSSSEQSDSSSFSIKATHLPIPR
GPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIVTR
IVELLGRRGWEALKYWWNLLQYWSQELKNSAVNLLNATAIAVAEGTDRVIEVL
QAAYRAIRHIPRRIRQGLERILL-Stop
+2
SA7SD4
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Fig. 5. (A) Amino acid sequence of the ORF in pLTR-ctat/crev encoding 138aa of the Env-CT. The sequence between the ﬁrst upstream stop codon and the Env stop codon is
depicted. The junction between SD4 and SA7 is shown. The Env-CT tryptic peptides identiﬁed by MSMS sequencing are boxed in grey. The peptide ATHLPIPR which spans the
SD4-SA7 junction is boxed in hatched grey. The mutated aa in pLTR-ctat/crev (Kþ2-stop) is underlined and labelled. (B) MSMS spectrum of peptide ATHLPIPR. A doubly
protonated peptide with m/z¼452.77 was selected for fragmentation. The sequence …HLPIPR is clearly detected by the y-fragments 1 to 6. The difference between peptide
mass and the mass of the y6 fragment can only be explained by an N-terminal alanine given that the second amino acid threonine is correct. (C) Western blot analysis,
employing Env-CT (Chessie 8) antibodies of pLTR-ctat/crev and the derivative pLTR-ctat/crev-(Env-CTþ2 stop). The position of the Env-CT* proteins is given on the left and of
molecular weight markers in the middle.
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Env-CT* moieties conﬁrming that they contain N-terminal aa in
the upstream reading frame.Discussion
In this study we describe the detection and preliminary
analysis of several novel protein entities containing amino acid
sequences from the HIV Env cytoplasmic C-terminus. The product
Tr-Env-CT has been demonstrated to consist of the last 139 aa of
Env (Env aa 718–856) in which the N-terminal aa Q718 has been
modiﬁed to pyroglutamic acid (5′-oxoproline (pGlu)) (see Fig. 6).
N-terminal pGlu modiﬁcation is present on a number of peptide
hormones, notably on thyrotropin-releasing hormone (TRH) and
gonadotropin-releasing hormone (GnRH), as well as on secretory
proteins such as neurotensin and ﬁbronectin (Vale et al., 1981).
Furthermore, signiﬁcant amounts of beta-amyloid (Aß) peptides,
involved in Alzheimer's disease, carry N-terminal pGlu (Saido
et al., 1995, 1996). The tissue distribution of the enzyme catalysing
this modiﬁcation, glutaminyl cyclase (QC), was initially described
to be chieﬂy restricted to regions of the brain (Pohl et al., 1991).
However, subsequently, an isoenzyme (isoQC) with similar activity
but only about 45% sequence homology was described to have
virtually ubiquitous tissue distribution (Cynis et al., 2008). The
isoQC enzyme is subcellularly localised to the Golgi complex
where it is believed to play a general role in the protein-
maturation machinery of the secretory pathway (Cynis et al.,
2008). The general consequence of N-terminal modiﬁcation to
pGlu is to increase peptide or protein stability and increase
biological activity. In this study, only N-terminally modiﬁed (and
no unmodiﬁed) QTHLPIPR peptide was detected which stronglypoints to the modiﬁcation being catalysed intracellularly by isoQC.
At present, no biological activity has been assigned to the Tr-Env-
CT protein. However, if this becomes available, the use of inhibitors
of QC enzyme may be employed to analyse the possible involve-
ment of the N-terminal pGlu.
As shown here, expression of full-length Env glycoprotein is a
prerequisite for the generation of Tr-Env-CT making it likely that it
is a product of proteolytic processing of the full-length molecule.
However the HIV protease itself does not appear to be the
processing molecule. This is in contrast to the situations with
the lentivirus equine infectious anemia virus (EIAV) and the
further retroviruses murine leukemia virus (MuLV) and Mason
Pﬁzer virus (MPV). In these cases, proteolytic removal of the C-
terminal domains of the respective transmembranal glycoproteins
is carried out by the respective viral protease enzymes and is
required to activate Env-mediated membrane fusion in virus
particles (Brody et al., 1994; Green et al., 1981; Rein et al., 1994;
Rice et al., 1990). Furthermore, in the case of certain mutant HIVs,
selected for resistance to the cholesterol-binding compound
amphotericin B methyl ester (AME), the viral protease enzyme
does actually cleave the HIV-Env-CT region from the transmem-
branal gp41 protein (Waheed et al., 2007). However in the case of
Tr-Env-CT entity described here, since the HIV protease does not
appear to play a role, it is likely that cleavage is carried out by a
cellular protease. Since modiﬁcation of Q718 by isoQC would likely
occur within the Golgi complex, proteolytic cleavage to (initially
unmodiﬁed) Tr-Env-CT would be assumed either to take place
there or prior to Env transport from the endoplasmatic reticulum.
Proteolytic cleavage of gp160 to gp120 and gp41 also takes place
within the Golgi complex making it possible that Tr-Env-CT is
derived from either gp160, gp41 or both. We have shown that
Tr-Env-CT is still generated when non-cleavable gp160, with a
Fig. 6. Schematic representation of the Env-CT species described in this paper. In the HIV glycoprotein, the region in the Env-CT between Env aa 706 and 732 is expanded.
The Chessie 8 epitope between aa 727 and 732 is hatched and the position of the splice acceptor site 7 (SA7) between aa 718 and 719 is shown. Splicing between splice donor
site 4 (SD4, nucleotides 6046/6047) and SA7 is schematically depicted. The dimensions of Tr-Env-CT and the spliced Env-CT* species are shown schematically. The positions
of Aþ1, detected by mass spectrometry, and Kþ2, which has been mutated to stop, are shown. The unknown translation start position of the Env-CT* species is indicated by
a question marks (?).
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and Pawlita, 1990) was expressed (data not shown) but this does
not necessarily need to hold true in the wild type situation.
Concerning the amino acid sequence requirement for Tr-Env-
CT generation, we have demonstrated that the sequence of the HIV
Env membrane spanning domain, which is located only 12 aa
N-terminal to Q718, is not of importance. The 12 amino acids
upstream of Q718 and prior to the Env membrane anchor are very
highly conserved in all HIV-1 Envs and it is conceivable that they
form part of a protease recognition domain. We have mutated
these amino acids and further amino acids surrounding Q718 itself
and analysed the properties of the mutated Envs. These studies
were, however, hampered by the fact that the sequence for
splicing at splice acceptor 7 (SA7, to the second tat and rev coding
exons) overlaps with Q718 and several other neighbouring codons.
Actually, the analyses did not yield further information since the
introduced changes either did not prevent generation of Tr-Env-CT
or adversely inﬂuenced splicing at SA7 (data not shown). However,
it has to be remembered that many proteases actually do not have
strict substrate sequence requirements but rather recognize con-
formational features. Finally though, it cannot strictly be ruled out
that the Tr-Env-CT entity may be the product of unspeciﬁc
proteolysis. However, as shown in Table 1, evaluation of the
relative intensities of peptides isolated from both the puriﬁed
gp41 and Tr-Env-CT proteins showed that, at any rate in trans-
fected 293 T cells, the amount of Tr-Env-CT is not much lower than
that of gp41. This rather indicates, but does not yet prove, that
Tr-Env-CT is a speciﬁc product and presumably serves a presently
unknown function during HIV infection in vivo.
Since the slightly larger species, designated Env-CT*, are
independent (Fig. 1) of expression of Env protein, it was likely
that they were products of spliced HIV mRNAs. Conﬁrming this,
we observed that proviral pNL-(rev-), encoding mutated, non-
functional Rev protein and failing to express Gag and full-length
Env proteins, expressed considerably increased amounts of the
heterogeneous Env-CT* species. This suggested that Env-CT*
species may be expressed from spliced mRNAs which are pre-
dominantly transported to the cytoplasm in the absence of Rev.
Conﬁrming this, Env-CT* species were also expressed from the
subgenomic construct pLTRctat/crev in which SD4 has been fused
to SA7 (i.e. to the second coding exons of tat and rev). In this
construct, Env sequences from aa 1–718 are absent but, as is the
case for all natural tat and rev transcripts, the last 138 C-terminal
aa of Env (719–856), containing the Chessie 8 epitope, are present
and overlap with the tat and rev second coding exons.
The questions which were then of interest concerned ﬁrst, the
identities of the different Env-CT* species and second, how theyare expressed. We have performed preliminary investigation of
these issues. As a ﬁrst step, we could show that all of the Env-CT*
species contain the Env protein C-terminus since they were all
increased in size when a Flag sequence was fused to the Env C-
terminus. Since all of the Env-CT* species are larger than Tr-Env-CT
(Env aa 718–856), it is to be expected that they contain additional
non-Env N-terminal aa. In the tryptic peptide, ATHLPIPR, which
was identiﬁed from the upper Env-CT* band by mass spectro-
metry, the N-terminal alanine is derived from the in-frame
sequence upstream of the Env sequence. The presence of N-
terminal in-frame amino acids upstream of Env aa T719 is
presumably to be expected since in pLTR-ctat/crev SD4 is fused
to SA7. Due to limitations in protein amounts, no further informa-
tion could be derived from these mass spectrometric analyses.
However, by introducing a stop codon at the þ2 position in the N-
terminal in-frame region (Kþ2), we could conﬁrm that the Env-
CT* species carry N-terminal in-frame aa. In Fig. 6, the position of
the residues in Env-CT* within the HIV genome are schematically
shown. Concerning translational initiation of Env-CT*, it is of note
that there are no potential initiation methionines in the in-frame
upstream region (see Fig. 5A). Thus it is likely that the Env-CT*
species are expressed from one or several multiply spliced mRNAs
i.e. from transcripts which have been additionally spliced
upstream from SD4. Expression from different multiply spliced
transcripts could explain the fact that Env-CT* consists of distinct
species. On the other hand, it cannot be ruled out that post-
translational processing or modiﬁcation of initially translated
species could account, at least in part, for the heterogeneity
observed. These issues are beyond the scope of the present study
but remain to be addressed in the future.
At steady state, Env-CT* species expression from wild type
provirus is not very high (Fig. 1B) so that it cannot be ruled out
that its detection from the mutated and subgenomic plasmids
described here is only an artefact. On the other hand, the expres-
sion of the set of Env-CT* proteins is very robust in the absence of
Rev protein (Fig. 4). This raises the possibility that at early time
points post-infection, before Rev levels are high, Env-CT* species
may be expressed and be of importance.
At present we do not have any information as to the possible
roles, if any, which the novel Env-CT species described here may
play in HIV infection in vivo. As mentioned in the Introduction,
several cellular proteins interact with the Env-CT domain and it is
possible that these proteins functionally interact with Tr-Env-CT or
Env-CT* species rather than with full-length Env protein. We have
previously shown that the heterodimer of prohibitin 1 and prohi-
bitin 2 (Phb1/Phb2) is an interaction partner of the Env-CT and,
in fact, in coimmunoprecipitation experiments it bound more
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than to full-length Env (Emerson et al., 2010b). Future experiments
are required to shed further light on these issues.Methods
Constructs
We have employed the proviral construct pNL4-3BH10env (Wilk
et al., 1992), referred to here as pNL-Wt, in this study. Nucleotide
numbering given here is from pNL4-3 (Adachi et al., 1986) and Env
amino acid (aa) numbering from strain BH10-Env (Ratner et al.,
1985). Due to introduced stop codons, pNL-Env-Tr712 and pNL-
Env-Tr813 encode for truncated Env proteins of 712 and 813 aa,
respectively (Wilk et al., 1992). In pNL-TMD-CD22, the HIV-Env
transmembrane domain (aa 684–705) has been replaced with that
of the type 1 membrane protein CD22 (Wilk et al., 1996). pNL-
ΔEnv does not express Env protein due to an introduced frame-
shift at the beginning of the env gene (Henriksson and Bosch,
1998). pNL-(rev-) encodes defective truncated Rev protein (Rev-
Tr62). It was generated employing the oligonucleotide 5′
CGGATCCTCAGCTGTTAGCTGGGACG 3′ (mismatched nucleotides
underlined in bold,) which also introduces a PvuII restriction site
and 3 conservative aa changes within the overlapping Env protein.
The provirally derived construct, referred to here as pLTRctat/crev,
expresses Tat and Rev proteins from cDNAs and has been
described previously (Schaal et al., 1993). In this construct splice
donor 1 (SD1) has been joined to splice acceptor 2 (SA2) and SD4
to SA7. The derivative pLTR-ctat/crev (rev-) encodes Rev protein
with the same mutation as described above. In the derivative
pLTR-ctat/crev-Flag, three tandem Flag epitopes (total aa sequence
DYKDHDGDYKDHDIDYKDDDDKA) have been introduced in frame
at the C-terminus of the sequence potentially encoding the
C-terminal 138 aa of the Env-CT (Env aa 719–856). In the further
derivative pLTR-ctat/crev-(Env-CTþ2 stop), the potential K residue
two aa upstream (i.e. 5′) of the Env-CT sequence has been mutated
to stop (TAG) (see Fig. 5A). pßAc-Env-Wt is a subviral expression
vector for strain BH10-Env, (Sal1-Xho1 fragment from pNL4-
3BH10env, nucleotides 5785–8887 (pNL4-3 numbering)) under con-
trol of the ß-actin promoter (Krausslich et al., 1993) while the
derivative pßAc-Env-Tr752 encodes truncated Env protein of 752
aa (Wilk et al., 1992). A further subviral Env expression vector is
pCMV-Env, again containing the HIV Sal1-Xho1 fragment, in this
case under control of the CMV immediate early promoter. The
derivative pCMV-Env-Flag has been generated by introducing
three tandem Flag epitopes in frame at the C-terminus of the
Env protein. Env expression from pCMV-Env is enhanced by
coexpression of Rev protein which was achieved from pCMV-
srev (Mermer et al., 1990). pTHRO4156 clone 18 (accession number
AY835448) (Li et al., 2005) is an expression vector for subtype B
Env glycoprotein with 20% diversity as compared to BH10 Env. It
was obtained from the NIH AIDS Research and Reference Reagent
programme. The construct prec.Env-CT was generated by standard
PCR procedures and encodes an N-terminal start methionine
followed by Env aa 706–856 under control of the EF1-α promoter
in the vector pWPXLd (kindly provided by D. Trono, Geneva,
Switzerland) from which the gene for GFP had been excised.
pMD.G is an expression vector for the G glycoprotein of vesicular
stomatitis virus (VSV-G) (Naldini et al., 1996).
Protein expression
293 T cells were cultivated in Dulbecco's modiﬁed Eagle's
medium, 10% fetal calf serum (FCS) and C8166 T-cells in RPMI
medium, 10% FCS. 293 T cells were transfected with the respectiveconstructs, in one experiment in the presence of 3 μM HIV
protease inhibitor Saquinavir, and at 48 h post-transfection (p.t.),
cell lysates were prepared in gel electrophoresis sample buffer
(containing 2% SDS, 5% mercaptoethanol). In order to efﬁciently
express pNL-Env-Tr712 (and pNL-Wt) in H9 cells, pseudotyped Wt
and mutant virions were generated in 293 T cells by cotransfection
of the respective proviral constructs with pMD.G. Forty-eight
hours p.t., aliquots of culture supernatants were used to infect
H9 T-cells and after removal of input virions and washing, the
infected cells were further incubated for 48 h and, subsequently
cell lysates prepared. Aliquots of cell lysates were separated on
precast NuPAGE Bis–Tris 4–12% polyacrylamide gels run with the
supplied MES SDS running buffer (Novex Life Technologies).
Western blot analysis employing mouse anti-gp41 (Chessie 8)
recognising an epitope within the Env-CT (aa 727–732 (PDRPEG)
of LAI gp160 (Abacioglu et al., 1994)), rabbit anti-gp160 serum
prepared in our laboratory against gel puriﬁed gp160 protein
expressed in insect cells, anti-p24 (183-H12-5C), anti-Flag mono-
clonal antibody M2 (Sigma-Aldrich, USA) or mouse anti-CD4 mAb
SIM2 was performed as previously described (Emerson et al.,
2010a).
Immunoprecipitation of proteins for mass spectrometric analysis
Two large plates (18 cm diameter) of 293 T cells were trans-
fected with either pßAc-Env-Wt or pLTRctat/crev. Forty-eight
hours p.t., the cells were suspended in medium (this achieved by
strong pipetting), centrifuged, washed once with 10 ml phosphate
buffered saline (PBS) and the cell pellets taken up in 1% Triton-X-
100 in PBS containing protease inhibitor cocktail (Roche Diagnos-
tics, Mannheim, Germany). After incubation for 10 min. on ice, the
lysates were clariﬁed by centrifugation at 2700 g for 5 min. and
the supernatants used further.
Prior to generation of the lysates, aliquots of washed Gamma-
Bind Plus Sepharose beads (GE Healthcare Biosciences, Uppsala,
Sweden) (each equivalent to 100 μl slurry) were incubated with
either 500 μl SIM2 (containing mAbs against CD4) or anti-gp41
Chessie 8 hybridoma supernatants (each containing approx. 5 μg
IgG) plus 500 μl 1% Triton-X-100 in PBS for 5 h at 4 1C with gentle
agitation and subsequently washed. To reduce potential unspeciﬁc
binding, cell lysates were ﬁrst incubated for 1 h with SIM2-bound
beads and, after removal of these by centrifugation, overnight at
4 1C with Chessie 8-bound beads. Both the SIM2- and the Chessie
8-beads were washed ﬁve times with 1% Triton-X-100 in PBS and
bound proteins dissolved in gel electrophoresis sample buffer.
Aliquots of the original lysates and of the unspeciﬁcally (SIM2) and
speciﬁcally (Chessie 8) bound proteins were subjected to Western
blot analysis to conﬁrm and quantify speciﬁc immunoprecipitation
(in general 10–20% of the Chessie 8 reactive proteins in the lysates
were speciﬁcally immunoprecipitated). The total remaining
amount (495%) of the proteins bound to the Chessie 8 beads
were then applied to a gel and stained with Coomassie blue. With
guidance from applied marker proteins, slices of the gel at the
positions of the proteins of interest were excised for further use.
Mass spectrometric analysis
Excised gel pieces were transferred to a 96-well plate and
reduced, alkylated and digested with trypsin as described pre-
viously (Catrein et al., 2005). Peptides were extracted from the gel
pieces with 50% acetonitrile/0.1% TFA, concentrated almost to
dryness in a vacuum centrifuge and diluted to a total volume of
30μl with 0.1% TFA. 25 μl of the sample were analysed in a
nanoHPLC system (Eksigent Technologies, Axel Semrau GmbH &
Co., 45549 Sprockhövel, Germany) coupled to an ESI LTQ Orbitrap
mass spectrometer (ThermoFisher Scientiﬁc). The sample was
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Sciences) with a ﬂow rate of 10 μl 0.1% TFA/min.. Peptides were
eluted and separated on an analytical column (75 μm150 mm)
packed with Inertsil 3 μm C18 material (LC Packings, GL Sciences)
with a ﬂow rate of 200 nl/min in a gradient of buffer A (0.1% formic
acid) and buffer B (0.1% formic acid in acetonitrile): 0–6 min: 0–3%
buffer B; 6–60 min: 3–40% buffer B; 60–65 min: 60–90% buffer B.
One survey scan (res: 60000) was followed by 5 information
dependent product ion scans. Peptide sequencing by MS/MS was
performed in the ion trap analyser. Twoþ(2þ), 3þ and 4þ
charged ions were selected for fragmentation.
Tandem mass spectrometry (MS/MS) spectra were searched
against a small protein database (representing approximately 300
random database entries) containing, in the case of Tr-Env-CT, the
aa sequence of the Env protein of HIV strain BH10 (Ratner et al.,
1985) and, in the case of Env-CT*, the aa sequences of all the HIV
open reading frames (ORF) present in pLTR-ctat/crev (Schaal et al.,
1993) using the Mascot software (Matrix Science). The algorithm
was set to use semitrypsin as proteolytic speciﬁcity, which means
that only one trypsin cleavage site was required for peptide
generation. Carbamidomethyl was set as a ﬁxed modiﬁcation of
cysteine, and oxidized methionine and deamidation of asparagines
and glutamines as variable modiﬁcations. Mass tolerance was set
to 5 ppm and 0.5 Da for MS and MS/MS, respectively. After a ﬁrst
database search the error tolerant option of the Mascot software
was used to identify peptides carrying unknown modiﬁcations.
Peptides with a score value below a 5% probability to be false
positive were taken as good candidates and the MS/MS spectra of
these peptides were check manually. For label free peptide
quantitation the MaxQuant software (version 1.3.0.5) (Cox and
Mann, 2008) was used with the default parameters except that the
peptide false discovery rate was set to 5%, and the minimal ion
score was set to 30.Acknowledgments
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